Atomi Financial Group Inc. Reduces Stake in SPDR S&P Biotech ETF (NYSEARCA:XBI)

Atomi Financial Group Inc. has reduced its investment in the SPDR S&P Biotech ETF (NYSEARCA:XBI) by 4.8% during the third quarter. This adjustment was disclosed in a recent filing with the Securities and Exchange Commission (SEC). After the sale of 112 shares, Atomi Financial Group now holds 2,236 shares of the ETF, which are valued at approximately $221,000.

In addition to Atomi Financial Group's actions, other institutional investors and hedge funds have also changed their holdings in XBI. For example, Dynamic Advisor Solutions LLC increased its stake in the SPDR S&P Biotech ETF by 1.4% in the third quarter, acquiring an additional 209 shares, bringing its total to 15,276 shares valued at around $1.51 million.

Axiom Advisory LLC also reported a 1.8% growth in its holdings, now owning 24,704 shares worth about $2.43 million after purchasing 435 additional shares during the quarter. Alpha Cubed Investments LLC saw a smaller increase of 0.9%, adding 2,176 shares to reach a total of 233,368 shares valued at $23.06 million.

Furthermore, Ignite Planners LLC made a new investment in the SPDR S&P Biotech ETF, valued at roughly $238,000, while GAMMA Investing LLC significantly boosted its position by a staggering 7,173.3%, now holding 1,091 shares worth $108,000 after acquiring 1,076 additional shares.

Current Performance of SPDR S&P Biotech ETF

As of the most recent trading session, shares of the SPDR S&P Biotech ETF opened at $98.68. The fund's 50-day moving average stands at $98.54, while the 200-day moving average is at $94.17. The ETF's market capitalization is approximately $7.52 billion, featuring a price-to-earnings (PE) ratio of 11.47 and a beta of 1.11. Historically, the SPDR S&P Biotech ETF has a one-year low of $63.80 and a one-year high of $103.52.

Understanding the SPDR S&P Biotech ETF

The SPDR S&P Biotech ETF aims to closely replicate the returns and features of the S&P Biotechnology Select Industry Index. This index is focused on the biotechnology sector within the broader S&P Total Markets Index, which encompasses all U.S. common stocks listed across various exchanges, including the New York Stock Exchange and NASDAQ.

Atomi, SPDR, Biotech